Femoral Access-Site Complications with Tenecteplase versus Alteplase before Mechanical Thrombectomy for Large-Vessel-Occlusion Stroke

References

1. 1.↵
   1. Siddiqui AH,
   2. Waqas M,
   3. Neumaier J, et al

   . Radial first or patient first: a case series and meta-analysis of transradial versus transfemoral access for acute ischemic stroke intervention. J Neurointerv Surg 2021;13:687–92 doi:10.1136/neurintsurg-2020-017225 pmid:33632879

   Abstract/FREE Full Text
2. 2.↵
   1. Oneissi M,
   2. Sweid A,
   3. Tjoumakaris S

   . Access-site complications in transfemoral neuroendovascular procedures: a systematic review of incidence rates and management strategies. Oper Neurosurg (Hagerstown) 2020;19:353–63 doi:10.1093/ons/opaa096 pmid:32365203

   CrossRefPubMed
3. 3.↵
   1. Shapiro SZ,
   2. Sabacinski KA,
   3. Mantripragada K, et al

   . Access-site complications in mechanical thrombectomy for acute ischemic stroke: a review of prospective trials. AJNR Am J Neuroradiol 2020;41:477–81 doi:10.3174/ajnr.A6423 pmid:32079599

   Abstract/FREE Full Text
4. 4.↵
   1. Goyal M,
   2. Demchuk AM,
   3. Menon BK, et al

   ; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30 doi:10.1056/NEJMoa1414905 pmid:25671798

   CrossRefPubMed
5. 5.↵
   1. Jovin TG,
   2. Chamorro A,
   3. Cobo E, et al

   ; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–306 doi:10.1056/NEJMoa1503780 pmid:25882510

   CrossRefPubMed
6. 6.↵
   1. Campbell BCV,
   2. Mitchell PJ,
   3. Kleinig TJ, et al

   ; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009–18 doi:10.1056/NEJMoa1414792 pmid:25671797

   CrossRefPubMed
7. 7.↵
   1. Bracard S,
   2. Ducrocq X,
   3. Mas JL, et al

   ; THRACE Investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016;15:1138–47 doi:10.1016/S1474-4422(16)30177-6 pmid:27567239

   CrossRefPubMed
8. 8.↵
   1. Saver JL,
   2. Goyal M,
   3. Bonafe A, et al

   ; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285–95 doi:10.1056/NEJMoa1415061 pmid:25882376

   CrossRefPubMed
9. 9.↵
   1. Broderick JP,
   2. Palesch YY,
   3. Demchuk AM, et al

   ; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893–903 doi:10.1056/NEJMoa1214300 pmid:23390923

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Fischer U,
    2. Kaesmacher J,
    3. Strbian D, et al

    ; SWIFT DIRECT Collaborators. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet 2022;400:104–15 doi:10.1016/S0140-6736(22)00537-2 pmid:35810756

    CrossRefPubMed
11. 11.↵
    1. Zi W,
    2. Qiu Z,
    3. Li F, et al

    ; DEVT Trial Investigators. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial. JAMA 2021;325:234–43 doi:10.1001/jama.2020.23523 pmid:33464335

    CrossRefPubMed
12. 12.↵
    1. LeCouffe NE,
    2. Kappelhof M,
    3. Treurniet KM,et al

    ; MR CLEAN–NO IV Investigators. A randomized trial of intravenous alteplase before endovascular treatment for stroke. N Engl J Med 2021;385:1833–44 doi:10.1056/NEJMoa2107727 pmid:34758251

    CrossRefPubMed
13. 13.↵
    1. Yang P,
    2. Zhang Y,
    3. Zhang L, et al

    ; DIRECT-MT Investigators. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med 2020;382:1981–93 doi:10.1056/NEJMoa2001123 pmid:32374959

    CrossRefPubMed
14. 14.↵
    1. Tanswell P,
    2. Modi N,
    3. Combs D, et al

    . Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41:1229–45 doi:10.2165/00003088-200241150-00001 pmid:12452736

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Huang X,
    2. Moreton FC,
    3. Kalladka D, et al

    . Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke 2015;46:3543–46 doi:10.1161/STROKEAHA.115.011290 pmid:26514192

    Abstract/FREE Full Text
16. 16.↵
    1. Tsivgoulis G,
    2. Katsanos AH,
    3. Christogiannis C, et al

    . Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke. Ann Neurol 2022;92:349–57 doi:10.1002/ana.26445 pmid:35713213

    CrossRefPubMed
17. 17.↵
    1. Mahawish K,
    2. Gommans J,
    3. Kleinig T, et al

    . Switching to tenecteplase for stroke thrombolysis: real-world experience and outcomes in a regional stroke network. Stroke 2021;52:e590–93 doi:10.1161/STROKEAHA.121.035931 pmid:34465202

    CrossRefPubMed
18. 18.↵
    1. Zhong CS,
    2. Beharry J,
    3. Salazar D, et al

    . Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke 2021;52:1087–90 doi:10.1161/STROKEAHA.120.030859 pmid:33588597

    CrossRefPubMed
19. 19.↵
    1. Gerschenfeld G,
    2. Liegey JS,
    3. Laborne F-X, et al

    . Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: insights from the TETRIS registry. EurStroke J 2022;7:358–64 doi:10.1177/23969873221113729 pmid:36478758

    CrossRefPubMed
20. 20.↵
    1. Menon BK,
    2. Buck BH,
    3. Singh N, et al

    ; AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022;400:161–69 doi:10.1016/S0140-6736(22)01054-6 pmid:35779553

    CrossRefPubMed
21. 21.↵
    1. Li S,
    2. Pan Y,
    3. Wang Z, et al

    . Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol 2022;7:47–53 doi:10.1136/svn-2021-000978 pmid:34429364

    Abstract/FREE Full Text
22. 22.↵
    1. Ma P,
    2. Zhang Y,
    3. Chang L, et al

    . Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis. J Neurol 2022;269:5262–71 doi:10.1007/s00415-022-11242-4 pmid:35776193

    CrossRefPubMed
23. 23.↵
    1. Katsanos AH,
    2. Psychogios K,
    3. Turc G, et al

    . Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. JAMA Netw Open 2022;5:e224506 doi:10.1001/jamanetworkopen.2022.4506 pmid:35357458

    CrossRefPubMed
24. 24.↵
    1. Yogendrakumar V,
    2. Beharry J,
    3. Churilov L, et al

    . Tenecteplase improves reperfusion across time in large vessel stroke. Ann Neurol 2023;93:489–99 doi:10.1002/ana.26547 pmid:36394101

    CrossRefPubMed
25. 25.↵
    1. Hendrix P,
    2. Collins MK,
    3. Griessenauer CJ, et al

    . Tenecteplase versus alteplase before mechanical thrombectomy: experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic. J Neurointerv Surg 2022 Nov 22. [Epub ahead of print] doi:10.1136/jnis-2022-019662 pmid:36414389

    Abstract/FREE Full Text
26. 26.↵
    1. Campbell BC,
    2. Mitchell PJ,
    3. Churilov L, et al

    ; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018;378:1573–82 doi:10.1056/NEJMoa1716405 pmid:29694815

    CrossRefPubMed
27. 27.↵
    1. Catapano JS,
    2. Rumalla K,
    3. Farhadi DS, et al

    . Safety and efficacy of radial versus femoral artery access for mechanical thrombectomy procedures following intravenous administration of tissue plasminogen activator. Stroke Vasc Interv Neurol 2022;2:e000238 doi:10.1161/SVIN.121.000238

    CrossRef
28. 28.↵
    1. Wu PJ,
    2. Dai YT,
    3. Kao HL, et al

    . Access site complications following transfemoral coronary procedures: comparison between traditional compression and angioseal vascular closure devices for haemostasis. BMC Cardiovasc Disord 2015;15:34 doi:10.1186/s12872-015-0022-4 pmid:25956814

    CrossRefPubMed
29. 29.↵
    1. Gerschenfeld G,
    2. Smadja D,
    3. Turc G

    ; et al; TETRIS Study Group. Functional outcome, recanalization, and hemorrhage rates after large vessel occlusion stroke treated with tenecteplase before thrombectomy. Neurology 2021;97:e2173–84 doi:10.1212/WNL.0000000000012915 pmid:34635558

    Abstract/FREE Full Text
30. 30.↵
    1. Farouque HM,
    2. Tremmel JA,
    3. Raissi Shabari F, et al

    . Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 2005;45:363–68 doi:10.1016/j.jacc.2004.10.042 pmid:15680713

    FREE Full Text
31. 31.↵
    1. Naddaf A,
    2. Williams S,
    3. Hasanadka R, et al

    . Predictors of groin access pseudoaneurysm complication: a 10-year institutional experience. Vasc Endovascular Surg 2020;54:42–46 doi:10.1177/1538574419879568 pmid:31578127

    CrossRefPubMed
32. 32.↵
    1. Kwok CS,
    2. Kontopantelis E,
    3. Kinnaird T, et al

    . Retroperitoneal hemorrhage after percutaneous coronary intervention: incidence, determinants, and outcomes as recorded by the British Cardiovascular Intervention Society. Circ Cardiovasc Interv 2018;11:e005866 doi:10.1161/CIRCINTERVENTIONS.117.005866 pmid:29445000

    Abstract/FREE Full Text
33. 33.↵
    1. Shaban S,
    2. Rastogi A,
    3. Phuyal S, et al

    . The association of transradial access and transfemoral access with procedural outcomes in acute ischemic stroke patients receiving endovascular thrombectomy: a meta-analysis. Clin Neurol Neurosurg 2022;215:107209 doi:10.1016/j.clineuro.2022.107209 pmid:35290788

    CrossRefPubMed